Zoic Capital
VC Fund
Bellevue, United States
Zoic Capital is a VC fund in Bellevue focused on Health Care and Biotechnology. Zoic Capital is the only US-based venture firm focused on early-stage healthcare innovations at the intersection of life sciences and medical technology.Promising Scientific Advancements: We look for breakthroughs with the potential for broad IP and commercial-ready maturity. We invest in roadmaps that leverage a core innovation across manyapplications and industries.Focus on Life Sciences: We see the most exciting advancements coming from life sciences labs, becoming tools that maintain and treat our health. We look at both technologies that enable development and care delivery devices.We Follow the Numbers: We follow our gut, but we also reinforce each of our decisions with numbers. We believe that merging qualitative and quantitative analysis is the best way to make successful investment decisions.Mentored Capital: We have the skills, experience and network to help, working closely with select teams to transform research into high impact, market-ready products.Milestone-Based Investing: We craft unique deal structures for each portfolio company based on mutually defined milestones. We find this approach creates ongoing momuntum and sets us all up for success.
- Total investments:
- 25
- Last investment:
- Lead investor:
- 64%
- Fund size:
- $380k
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Zoic Capital invests in
Stages Zoic Capital invests in
Countries Zoic Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $3M–$4M
- Series A
- $7.2M–$7.2M
Investment Focus
Industry
- Health Care 6 (24%)
- Biotechnology 6 (24%)
- Medical 3 (12%)
- Medical Device 3 (12%)
- Manufacturing 2 (8%)
Stage
- Seed 5 (20%)
- Series A 2 (8%)
- Series B 1 (4%)
- Convertible Note 1 (4%)
- Venture - Series Unknown 1 (4%)
Country
- United States 7 (28%)
- Canada 2 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ian Eliason
Principal, Strategy & Operations
|
Principal, Strategy & Operations | Total investments: 7 | Find email | |
Ann Revell-Pechar
Communications Director
|
Communications Director | Total investments: 0 | Find email | |
Lahav Gil
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Neal Mody
Partner & Managing Director
|
Partner & Managing Director | Total investments: 8 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Trio Labs
|
Trio Labs is a digital manufacturing technology company producing high volume manufacturing of precision metal and ceramic 3D printing. The company's technology eliminates costs associated with tooling and increases the throughput of established high-volume production processes, enabling engineers to match the precision of existing systems, toproduce metals and ceramics at high volumes and speeds, and to do so affordably than using conventional manufacturing techniques.It was founded in 2015 and is headquartered in Durham, NC. | Series A / Feb 29, 2024 | |
ProbiusDx
|
ProbiusDx is an electronic sensing company that provides a diagnostic technology for detecting and monitoring blood concentrations. | $3M / Series B / May 31, 2023 | |
Chromatan
|
ChromaTan is solving a major process bottleneck in therapeutic protein production while significantly lowering the cost of goods for biotech and contract manufacturing companies. Our CCTC platform provides an inexpensive column-free, continuous, and single-use solution that will replace large scale column chromatography processes used in biologicsmanufacturing. The platform has been through extensive beta testing with over a dozen of major biotech companies and has consistently shown a 5-15X increase in throughput at an equivalent or better product quality. | Seed / Feb 01, 2023 | |
HDT Bio
|
HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology. The company's technology platforms and products cover a wide range of immunotherapy modalities and mechanisms of action, including innate immunity activation, adaptive immune response amplification, and tumor-tight junction disruption. Its mission isto maintain the rapid and significant progress made in the fight against the world's deadliest infectious diseases by developing cutting-edge immunotherapy technologies in a cost-effective manner across leading markets as well as low or middle-income countries. | $3M / Seed / Feb 16, 2021 | |
|
ProbiusDx
|
ProbiusDx is an electronic sensing company that provides a diagnostic technology for detecting and monitoring blood concentrations. | $7.2M / Series A / Dec 01, 2020 | |
|
ProbiusDx
|
ProbiusDx is an electronic sensing company that provides a diagnostic technology for detecting and monitoring blood concentrations. | $7.2M / Series A / Dec 01, 2020 | |
|
ProbiusDx
|
ProbiusDx is an electronic sensing company that provides a diagnostic technology for detecting and monitoring blood concentrations. | $7.2M / Series A / Dec 01, 2020 | |
|
HDT Bio
|
HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology. The company's technology platforms and products cover a wide range of immunotherapy modalities and mechanisms of action, including innate immunity activation, adaptive immune response amplification, and tumor-tight junction disruption. Its mission isto maintain the rapid and significant progress made in the fight against the world's deadliest infectious diseases by developing cutting-edge immunotherapy technologies in a cost-effective manner across leading markets as well as low or middle-income countries. | $4M / Seed / Oct 05, 2020 | |
|
HDT Bio
|
HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology. The company's technology platforms and products cover a wide range of immunotherapy modalities and mechanisms of action, including innate immunity activation, adaptive immune response amplification, and tumor-tight junction disruption. Its mission isto maintain the rapid and significant progress made in the fight against the world's deadliest infectious diseases by developing cutting-edge immunotherapy technologies in a cost-effective manner across leading markets as well as low or middle-income countries. | $4M / Seed / Oct 05, 2020 | |
|
HDT Bio
|
HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology. The company's technology platforms and products cover a wide range of immunotherapy modalities and mechanisms of action, including innate immunity activation, adaptive immune response amplification, and tumor-tight junction disruption. Its mission isto maintain the rapid and significant progress made in the fight against the world's deadliest infectious diseases by developing cutting-edge immunotherapy technologies in a cost-effective manner across leading markets as well as low or middle-income countries. | $4M / Seed / Oct 05, 2020 | |
| See all 25 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Zoic Capital invest in?
Zoic Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Zoic Capital's check size?
Zoic Capital typically joins rounds of $3M–$4M at Seed and $7.2M–$7.2M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Zoic Capital participates in.
How do I contact Zoic Capital?
Public channels for Zoic Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Zoic Capital?
The team at Zoic Capital includes Ian Eliason (Principal, Strategy & Operations), Ann Revell-Pechar (Communications Director) and Lahav Gil (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
